Creative Biolabs stands as a pioneering biotechnology company committed to providing experimental services to researchers globally, with a focus on advancing gene therapy’s perfection and innovation alongside industry leaders.
In the backdrop of continuous technological advancements, particularly in gene editing, the gene therapy sector is poised for substantial growth. The annual increase in approved gene therapy products in the 21st century underscores the rapid development of this expansive field within medicine. Gene therapy is now seamlessly integrated into a broader spectrum of disease treatments, marking an era of unprecedented progress. Distinguishing itself from traditional small-molecule drugs and large-molecule biologics that operate at the protein level, gene therapy operates at the genetic level. This distinction allows gene therapy to overcome limitations faced by conventional drugs, such as the inability to interfere with protein-protein interactions for small molecules and the challenge for large-molecule biologics to target intracellular pathways.
A scientist at Creative Biolabs emphasizes, “Gene therapy possesses unique properties and advantages in targeting disease-causing genes that are evident at the genetic level, but pose challenges at the protein level. It holds the potential to cure diseases at their source—gene mutations. Depending on the technical approach, the FDA categorizes gene therapy products into plasmid DNA gene therapy products, viral vector gene therapy products, bacterial vector gene therapy products, etc.”
Genes transferred via viral vectors play a pivotal role in gene therapy clinical trials, surpassing the efficacy and specificity of physical and chemical methods. Creative Biolabs offers an extensive range of viral vector solutions and state-of-the-art technology for both basic research and preclinical applications. This includes the design and construction of tailored viral vectors, along with the capability for small- to large-scale viral vector production.
The Creative Biolabs scientist explains, “For example, lentiviral vectors are highly effective tools in molecular and cellular biology experiments, offering unique advantages in gene transfection. These vectors do not require cells to be in the mitotic phase, ensuring high gene transfection efficiency and the ability to accommodate large gene fragments. We actively promote the development of viral vectors for basic research or gene therapy through optimization, design, and safety testing.”
The vaccinia virus, once instrumental in eradicating smallpox through vaccination, possesses a linear double-stranded DNA genome of approximately 190 kb, with the capacity to accommodate over 30 kb of exogenous DNA. This unique characteristic allows exogenous genes to seamlessly integrate into the virus genome, facilitating efficient and prolonged gene expression. Redesigned attenuated vaccinia viruses, derived from various strains, have been scientifically validated as non-toxic and safe for human applications.
“We design and construct vaccinia virus vectors, providing a range of options including highly attenuated, host-restricted, non-replicating, or poorly replicating vaccinia virus strains. Examples include the NYVAC vector, the ALVAC vector, and the TROVAC vector, each tailored to meet diverse gene delivery requirements in global research.”
In the realm of gene therapy, whether employing integrated viral vectors or non-integrated counterparts, Creative Biolabs offers customizable design and development services. This capability significantly expedites gene therapy research for scientists seeking tailored solutions.
–Creative Biolabs release